AI assistant
Aura Biosciences, Inc. — Director's Dealing 2021
Oct 28, 2021
33080_dirs_2021-10-28_5406c2d3-89b7-4a7d-852e-5da074e6e380.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aura Biosciences, Inc. (AURA)
CIK: 0001501796
Period of Report: 2021-10-28
Reporting Person: Rich Cadmus (See Remarks)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.21 | 2027-10-11 | Common Stock (29197) | Direct | |
| Stock Option (Right to Buy) | $2.74 | 2028-02-21 | Common Stock (80291) | Direct | |
| Stock Option (Right to Buy) | $3.15 | 2029-02-06 | Common Stock (18248) | Direct | |
| Stock Option (Right to Buy) | $4.25 | 2030-03-16 | Common Stock (41422) | Direct | |
| Stock Option (Right to Buy) | $5.48 | 2031-06-28 | Common Stock (125547) | Direct |
Footnotes
F1: The shares underlying this option are fully vested as of October 23, 2021.
F2: The shares underlying this option vest as follows: 25% of the shares vest on the first anniversary of February 21, 2018 with the remainder vesting thereafter pro-rata in 36 monthly installments.
F3: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2019
F4: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following February 6, 2020
F5: The shares underlying this option vest in 48 monthly installments, equal to 2.0833% of the shares, over the 48 months following June 28, 2021